Core Viewpoint - A class action lawsuit has been filed against Fortrea Holdings Inc. for allegedly misleading investors regarding its financial performance and projections following its spin-off from Labcorp Holdings Inc. [1][3][5] Company Overview - Fortrea Holdings was spun off from Labcorp Holdings in June 2023 and operates as a standalone publicly traded company [3]. - The company entered into transition services agreements with Labcorp, which include IT, finance, HR, and marketing support [3]. Financial Performance - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA targets for 2025 were not aligned with prior expectations, leading to a significant stock price drop of $3.47 per share, or 25.05%, closing at $10.38 [4]. - The company indicated that its Pre-Spin projects were underperforming, with less revenue and profitability than anticipated for 2025 [4]. Allegations in the Lawsuit - The complaint alleges that Fortrea overestimated revenue contributions from Pre-Spin projects and overstated cost savings from exiting transition services agreements [5]. - It is claimed that the company's previously announced EBITDA targets for 2025 were inflated, impacting the perceived viability of its post-Spin-Off business model [5].

Core Viewpoint - A class action lawsuit has been filed against Fortrea Holdings Inc. for allegedly misleading investors regarding its financial performance and projections following its spin-off from Labcorp Holdings Inc. [1][3][5] Group 1: Company Background - Fortrea Holdings was spun off from Labcorp Holdings in June 2023 as a standalone publicly traded company [3] - The company entered into transition services agreements with Labcorp, which include various administrative and IT support services [3] Group 2: Financial Performance - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA expectations for 2025 were not aligned with prior forecasts, leading to a significant stock price drop of 25.05% [4] - The company indicated that its Pre-Spin projects were underperforming, contributing less revenue and profitability than anticipated for 2025 [4] Group 3: Allegations in the Lawsuit - The complaint alleges that Fortrea overestimated revenue contributions from Pre-Spin projects and overstated cost savings from exiting transition services agreements [5] - It is claimed that the company's previously announced EBITDA targets for 2025 were inflated, impacting the perceived viability of its post-Spin-Off business model [5]

Core Viewpoint - A class action lawsuit has been filed against Fortrea Holdings Inc. for allegedly misleading investors regarding its financial performance and projections following its spin-off from Labcorp Holdings Inc. [1][3][5] Company Overview - Fortrea was spun off from Labcorp in June 2023 as a standalone publicly traded company [3] - The company entered into transition services agreements with Labcorp for various administrative and operational support [3] Financial Performance - On March 3, 2025, Fortrea disclosed that its revenue and adjusted EBITDA targets for 2025 were not aligned with prior expectations, leading to a significant stock price drop of 25.05%, closing at $10.38 per share [4] - The company indicated that its Pre-Spin projects were underperforming, contributing less revenue and profitability than anticipated for 2025 [4] Allegations in the Lawsuit - The complaint alleges that Fortrea overestimated revenue contributions from Pre-Spin projects and overstated cost savings from exiting transition services agreements [5] - It is claimed that the company's previously announced EBITDA targets for 2025 were inflated, misrepresenting the viability of its post-Spin-Off business model [5]

Core Viewpoint - A lawsuit has been filed against Fortrea Holdings Inc. and its senior executives for potential violations of federal securities laws, specifically related to the company's financial disclosures and performance claims [1][2]. Group 1: Company Background - Fortrea Holdings Inc. is a global contract research organization that provides biopharmaceutical product and medical device development solutions. It was spun off from Labcorp Holdings Inc. in June 2023 [3]. Group 2: Allegations and Financial Performance - The lawsuit alleges that Fortrea overstated the cost savings and margin improvements expected from exiting transition services agreements (TSAs) with Labcorp, as well as the revenue from pre-spin projects [4]. - Following a report from Jefferies on September 25, 2024, which indicated that the anticipated cost savings were not as significant as previously claimed, Fortrea's stock price fell by $2.73, or over 12%, from $22.21 to $19.48 per share [5]. - On March 3, 2025, Fortrea announced disappointing Q4 and full-year 2024 results, revealing lower-than-expected revenue and profitability from pre-spin projects, leading to a further decline in stock price by $3.47, or over 25%, from $13.85 to $10.38 per share [6].

Core Viewpoint - A lawsuit has been filed against Fortrea Holdings Inc. and its senior executives for potential violations of federal securities laws, stemming from allegations of overstating cost savings and revenue projections related to transition services agreements following its spin-off from Labcorp [1][2][4]. Group 1: Company Background - Fortrea Holdings Inc. is a global contract research organization that provides biopharmaceutical product and medical device development solutions. It was spun off from Labcorp Holdings Inc. in June 2023 [3]. Group 2: Allegations and Financial Impact - The lawsuit claims that Fortrea overstated the cost savings and margin improvements expected from exiting transition services agreements with Labcorp, as well as the revenue from pre-spin projects [4]. - Following a report from Jefferies on September 25, 2024, indicating that the anticipated cost savings were not as significant as previously thought, Fortrea's stock price fell by $2.73, or over 12%, from $22.21 to $19.48 per share [5]. - On March 3, 2025, Fortrea announced disappointing Q4 and full year 2024 financial results, revealing lower-than-expected revenue and profitability from pre-spin projects, leading to a further decline in stock price by $3.47, or over 25%, from $13.85 to $10.38 per share [6].

Core Viewpoint - A class action lawsuit has been filed against Fortrea Holdings Inc. for allegedly misleading investors regarding its financial performance and projections following its spin-off from Labcorp Holdings Inc. [1][3][5] Company Overview - Fortrea Holdings was spun off from Labcorp Holdings in June 2023 and operates as a standalone publicly traded company [3]. - The company entered into transition services agreements with Labcorp, which include various administrative and IT support services [3]. Financial Performance - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA targets for 2025 were not meeting prior expectations, leading to a significant stock price drop of 25.05%, closing at $10.38 per share [4]. - The company indicated that its Pre-Spin projects were underperforming, with less revenue and profitability than anticipated for 2025 [4]. Allegations in the Lawsuit - The complaint alleges that Fortrea overestimated revenue contributions from Pre-Spin projects and overstated potential cost savings from exiting transition services agreements [5]. - It is claimed that the company's previously announced EBITDA targets for 2025 were inflated, misrepresenting the viability of its post-spin business model [5].

Core Viewpoint - A lawsuit has been filed against Fortrea Holdings Inc. and its senior executives for potential violations of federal securities laws, following allegations of overstating cost savings and revenue projections related to transition services agreements after its spin-off from Labcorp [1][2][4]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, specifically titled Deslande v. Fortrea Holdings Inc., et al., No. 1:25-cv-04630 [2]. - Investors have until August 1, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - Fortrea is a global contract research organization that provides biopharmaceutical product and medical device development solutions, having been spun off from Labcorp in June 2023 [3]. Group 3: Allegations and Financial Impact - Allegations state that Fortrea exaggerated the cost savings and margin improvements expected from exiting transition services agreements, as well as the revenue from pre-spin projects [4]. - Following a report from Jefferies on September 25, 2024, which indicated that the anticipated cost savings were not as significant as claimed, Fortrea's stock price fell by $2.73, or over 12%, from $22.21 to $19.48 per share [5]. - On March 3, 2025, Fortrea announced disappointing Q4 and full-year 2024 results, leading to a further decline in stock price by $3.47, or over 25%, from $13.85 to $10.38 per share [6].

Core Viewpoint - A lawsuit has been filed against Fortrea Holdings Inc. and its senior executives for potential violations of federal securities laws, alleging that the company overstated cost savings and revenue projections related to its transition services agreements with Labcorp [1][2][4]. Group 1: Company Background - Fortrea Holdings Inc. is a global contract research organization that provides biopharmaceutical product and medical device development solutions. It was spun off from Labcorp Holdings Inc. in June 2023 [3]. Group 2: Allegations and Financial Impact - The lawsuit claims that Fortrea exaggerated the cost savings and margin improvements expected from exiting transition services agreements with Labcorp, as well as the revenue from pre-spin projects [4]. - Following a report from Jefferies on September 25, 2024, which indicated that the anticipated cost savings were not as significant as previously thought, Fortrea's stock price fell by $2.73, or over 12%, from $22.21 to $19.48 per share [5]. - On March 3, 2025, Fortrea announced disappointing Q4 and full year 2024 financial results, revealing lower-than-expected revenue and profitability from pre-spin projects, leading to a further decline in stock price by $3.47, or over 25%, from $13.85 to $10.38 per share [6].

Core Viewpoint - A class action lawsuit has been filed against Fortrea Holdings Inc. for allegedly misleading investors regarding its financial performance and projections following its spin-off from Labcorp Holdings Inc. [1][3][5] Group 1: Company Background - Fortrea Holdings was spun off from Labcorp Holdings in June 2023 as a standalone publicly traded company [3] - The company entered into transition services agreements with Labcorp to receive various administrative and IT support services [3] Group 2: Financial Performance - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA projections for 2025 were not meeting prior expectations, leading to a significant stock price drop of $3.47 per share, or 25.05%, closing at $10.38 [4] - The company indicated that its Pre-Spin projects were underperforming, with less revenue and profitability than anticipated for 2025 [4] Group 3: Allegations in the Lawsuit - The complaint alleges that Fortrea overestimated revenue contributions from Pre-Spin projects and overstated potential cost savings from exiting transition services agreements [5] - It is claimed that the company's previously announced EBITDA targets for 2025 were inflated, misrepresenting the viability of its post-Spin-Off business model [5]

Core Viewpoint - A lawsuit has been filed against Fortrea Holdings Inc. and its senior executives for potential violations of federal securities laws, specifically related to the company's financial disclosures and performance claims [1][2]. Group 1: Company Background - Fortrea Holdings Inc. is a global contract research organization that provides biopharmaceutical product and medical device development solutions. It was spun off from Labcorp Holdings Inc. in June 2023 [3]. - Following the spin-off, Fortrea entered into transition services agreements (TSAs) with Labcorp, agreeing to pay for certain transitional services over a specified period [3]. Group 2: Allegations and Financial Performance - The lawsuit alleges that Fortrea overstated the cost savings and margin improvements expected from exiting the TSAs, as well as the revenue from pre-spin projects [4]. - On September 25, 2024, a report from Jefferies indicated that the anticipated cost savings from exiting the TSAs were not as significant as previously claimed, leading to a stock price decline of $2.73 per share, or over 12% [5]. - On March 3, 2025, Fortrea announced disappointing Q4 and full year 2024 financial results, revealing lower-than-expected revenue and profitability from pre-spin projects, resulting in a further stock price decline of $3.47 per share, or over 25% [6].